Table 1. Display of the distribution of the outcome variables.
N denotes the sample size used for each outcome, while Positive and Negative denote the balance of the data.
| Outcome Variable | N | Positive | Negative |
|---|---|---|---|
| Molecular breast cancer subtypes | |||
| Luminal A | 95 | 58 (61%) | 37 (39%) |
| Luminal B | 95 | 16 (17%) | 79 (83%) |
| HER2-enriched | 95 | 6 (6%) | 89 (94%) |
| Triple-Negative | 95 | 15 (16%) | 80 (84%) |
| Differentiation of Molecular breast cancer subtypes | |||
| Luminal A vs Luminal B | 74 | 58 (78%) | 16 (22%) |
| Luminal A vs HER2-enriched | 64 | 58 (91%) | 6 (9%) |
| Luminal A vs Triple- Negative | 73 | 58 (79%) | 15 (21%) |
| Luminal B vs HER2-enriched | 22 | 16 (73%) | 6 (27%) |
| Luminal B vs Triple- Negative | 31 | 16 (52%) | 15 (48%) |
| HER2-enriched vs Triple-Negative | 21 | 6 (29%) | 15 (71%) |
| Receptor status | |||
| Estrogen Receptor (ER) | 95 | 73 (77%) | 22 (23%) |
| Progesterone Receptor (PR) | 95 | 66 (69%) | 29 (31%) |
| Hormone receptor positivity | 95 | 74 (78%) | 21 (22%) |
| Ki67- and HER2-Expression | |||
| Ki67 | 80 | 20 (25%) | 60 (75%) |
| Human epidermal growth factor receptor 2 (HER2) | 95 | 22 (23%) | 73 (77%) |
| Involvement of the lymphatic system | |||
| Lymph Vessel Involvement | 51 | 8 (16%) | 43 (84%) |
| Lymph Node Metastasis | 84 | 34 (40%) | 50 (60%) |
| Grading | |||
| Elston-Ellis Grading (EE) | 57 | 44 (77%) | 13 (23%) |
| Histological Grading | 90 | 18 (20%) | 72 (80%) |